Tarsus Pharmaceuticals, Inc.
TARS
Rankning i aktier
#4590
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aktiekurs
$71.12
Senast synkroniserad: 2026-10-20
Marknadsvärde
$3.33B
Förändring (1 dag)
2.33%
Förändring (1 år)
0.42%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Antal utestående aktier för Tarsus Pharmaceuticals, Inc. (TARS)
Antal utestående aktier per June 2026: 43.39M
Enligt de senaste finansiella rapporterna och aktiekursen för Tarsus Pharmaceuticals, Inc. är det aktuella antalet utestående aktier 43.39M. I slutet av December 2023 hade företaget 29.38M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Tarsus Pharmaceuticals, Inc. (TARS) från 2018 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 43.39M | 15.39% |
| 2024 | 37.60M | 27.98% |
| 2023 | 29.38M | 19.35% |
| 2022 | 24.62M | 19.78% |
| 2021 | 20.55M | 1.14% |
| 2020 | 20.32M | 4.17% |
| 2019 | 19.51M | 355.26% |
| 2018 | 4.29M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 485.11% |
US
|
|
| 396.00M | 812.58% |
US
|
|
| 478.91M | 1,003.65% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 43.31% |
NL
|
